Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | CCR3 | P51677 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20304240 | 0.89 | MEN1 (0.39) | GAALMNAMEN1KMT2AKDM4E | |
| SCHEMBL7572087 | 0.87 | ROCK2 (0.43) | LMNAMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL7568892 | 0.87 | KMT2A (0.48) | GAALMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL7538262 | 0.86 | RAB9A (0.45) | LMNAMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL7572847 | 0.85 | PARP1 (0.43) | GAAMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL7545741 | 0.85 | PKM (0.44) | LMNAMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL21772575 | 0.85 | EPHX1 (0.45) | LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7567622 | 0.84 | IDO1 (0.47) | GAALMNAMEN1KMT2AKDM4E | |
| SCHEMBL7552193 | 0.84 | PARP1 (0.47) | GAALMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL2963962 | 0.84 | ALDH1A1 (0.49) | LMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200069691-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-03-05 | — | — | US | claimed |
| EP-3558305-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2019-10-30 | — | — | EP | claimed |
| WO-2018118829-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | claimed |
| US-20200069691-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200069691-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069691-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | SERPINB1, PREP, PEPD | GAA 123/4885OPRK1 1872/4885LMNA 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.